<DOC>
	<DOCNO>NCT01937806</DOCNO>
	<brief_summary>To prove study drug noninferior control drug proportion subject show HBV DNA undetected ( less 400 copies/mL ( 69 IU/mL ) ) 48th week 48-week administration Besifovir 150 mg , Tenofovir 300 mg control drug chronic hepatitis B patient</brief_summary>
	<brief_title>Phase 3 Study Besifovir</brief_title>
	<detailed_description>- Screening Period Subject registration conduct confirm selection exclusion criterion write consent form obtain within 28 day clinical trial drug administration . - Wash-out Period Subjects treat antiviral agent within 12 week complete 4-week wash-out period stage stop antiviral agent treatment baseline visit subject experience antiviral agent treatment start baseline visit without wash-out period . - Baseline Subjects visit date start clinical trial drug administration randomize test group control group ratio 1:1 . Double blindness apply group . - Treatment period Subjects orally administer clinical trial drug q.ds.i.d . 48 week visit 0 , 4th , 12th , 24th , 36th , 48th week HBV DNA test , laboratory test , physical test , vital sign , adverse event . - Follow-up period Subjects provide appropriate treatment complete 48-week trial drop . Subjects visit 60th week follow-up adverse event , acute deterioration hepatitis B , HBV DNA test result . If treatment conduct 48-week administration , subject visit interval four week follow-up visit ( 60th week ) test 24th week visit ( Visit 5 ) conduct . However , subject participate 48-week separate extend trial conduct 48-week administration clinical trial follow-up period .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Male female patient age 20 year old 2 . Patients show positive HBsAg history chronic hepatitis B last six month screen 3 . Patients receive interferon ( include Pegylation formulation ) treat chronic hepatitis antiviral agent 12 week . 4 . Patients show positive HBsAg screen 5 . Patients show HBV DNA measure COBAS TaqManTM HBV Test 1x105 copies/mL ( 17,241 IU/mL ) case positive HBeAg screening , show HBV DNA measure COBAS TaqManTM HBV Test 1x104 copies/mL ( 1,724 IU/mL ) case negative HBeAg 6 . Patients show ALT 1.2 time , less 10 time upper limit normal range screen 7 . Patients explain purpose , method effect clinical trial , sign write consent form . 8 . Male female patient childbearing age use double contraception acknowledged* trial period * Double contraception acknowledge mean combination barrier contraception ( condom , diaphragm , etc . ) contraception ( sterilization operation , intrauterine contraceptive device , oral contraceptive drug , hormone delivery system , contraceptive cream , jelly foam , etc. ) . 1 . Patients hepatitis C ( HCV ) , hepatitis D ( HDV ) , human immunodeficiency virus ( HIV ) 2 . Patients uncompensated liver disease least one follow value sign screen Total bilirubin &gt; 2 x ULN Prothrombin time delay three second compare normal value Serum Albumin &lt; 30 g/L ( 3 g/dL ) A medical history ascites , jaundice , hemorrhage varix , hepatic encephalopathy , sign liver function loss 3 . At least one follow laboratory value screen Hemoglobin &lt; 9.0 g/dL Absolute neutrophil count ( ANC ) &lt; 1.5 x 109 /L ( 1500 /mm3 ) Platelet count &lt; 100 x 109 /L ( 100 x 103 /mm3 ) Serum creatinine &gt; 1.5 mg/dL Serum amylase &gt; 2 x ULN Lipase &gt; 2 x ULN 4 . Patients show GFR le 50 mL/min calculate MDRD ( Modification Diet Renal Disease : 1.86 x PCr 1.154 x AGE 0.203 ( x 0.742 woman ) ) screen 5 . Patients show alphafetoprotein ( AFP ) 50 ng/mL screen estimate hepatocellular carcinoma ( HCC ) liver/abdomen CT scan 6 . Patients receive follow drug last two month screen ( however , shortterm use ( less consecutive 14 day ) drug lowdose aspirin ( 100 mg , maximally , 300 mg/day ) allow . ) Nephrotoxic drug ( e.g . Aminoglycosides , Amphotericin B , NSAIDs ) Hepatotoxic drug ( e.g . Erythromycin , Ketoconazole , Rifampin , Fluconazole , Dapsone ) Anticoagulant ( e.g . Warfarin ) 7 . Patients suspect investigator level immunity decrease among patient administer immunosuppressant within six month screen 8 . Patients administer longterm general corticosteroid ( consecutive 14 day ) high dose ( prednisolone 20 mg daily* ) within three month screen ( In case local corticosteroid , investigator decides . ) * It equal cortisone 125 mg , hydrocortisone 100 mg , prednisone 20 mg , methylprednisolone 16 mg , triamcinolone 16 mg , dexamethasone 3 mg , betamethasone 2.4 mg. 9 . Patients diagnose malignant tumor within five year screen relapse malignant tumor ( In case benign tumor , investigator decides affect progress clinical trial trial period , patient register . ) 10 . Patients scheduled participate clinical trial register clinical trial , participate clinical trial within three month register clinical trial 11 . Pregnant woman , lactate woman , patient plan pregnancy trial period 12 . Patients hypersensitivity clinical trial drug clinical trial 13 . Patients past medical history clinical alcohol drug abuse within year screen abuser 14 . Patients severe disease , liver disease , heart failure , renal failure , pancreatitis , decide investigator effect clinical trial 15 . Patients hepatic disease ( hematochromatosis , Wilson 's disease , alcoholic liver disease , nonalcoholic steatohepatitis , Î±1antitrypsin deficiency ) except hepatitis B 16 . Patients receive organ transplant 17 . Persons possible decline daily function due mental disease patient able understand purpose method clinical trial 18 . Patients decide investigator unsuitable conduct clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Chronic hepatitis B</keyword>
</DOC>